Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers

The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028

Activity of Xoma 358, an Inhibitor of Insulin Action Following Short-Term Administration to Congenital Hyperinsulinism Patients

ENDO 2017 Annual Meeting

XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial

ENDO 2015 Annual Meeting

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia

mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience

The Extended Duration Single Dose Pharmacokinetics (PK) and Pharmacodynamics (PD) of AB101, a Potential Once Weekly Basal Subcutaneous (SC) Insulin, in Diabetic Miniature Swine

2016 American Diabetes Association Scientific Sessions

The in Vitro and in Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin

2015 American Diabetes Association Scientific Sessions

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening

Investigative Ophthalmology & Visual Science, May 2016; 57:2390–2399

Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats

Diabetes, 60:1590–1598, May 2011

Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular Permeability

Hypertension, February 2009; 53:175-181